NasdaqGM - Delayed Quote • USD
Reneo Pharmaceuticals, Inc. (RPHM)
At close: May 17 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | -0.16 | -0.14 | -0.74 | -0.38 |
| Low Estimate | -0.23 | -0.21 | -0.83 | -0.38 |
| High Estimate | -0.1 | -0.07 | -0.65 | -0.38 |
| Year Ago EPS | -0.65 | -0.57 | -2.52 | -0.74 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.52 | -0.57 | -0.58 | -0.44 |
| EPS Actual | -0.65 | -0.57 | -0.71 | -0.25 |
| Difference | -0.13 | 0 | -0.13 | 0.19 |
| Surprise % | -25.00% | 0.00% | -22.40% | 43.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.16 | -0.14 | -0.74 | -0.38 |
| 7 Days Ago | -0.2 | -0.17 | -0.88 | -0.53 |
| 30 Days Ago | -0.21 | -0.16 | -0.91 | -0.55 |
| 60 Days Ago | -0.18 | -0.17 | -0.79 | -0.56 |
| 90 Days Ago | -0.18 | -0.17 | -0.84 | -0.68 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RPHM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 75.40% | -- | -- | 8.00% |
| Next Qtr. | 75.40% | -- | -- | 12.40% |
| Current Year | 70.60% | -- | -- | 5.60% |
| Next Year | 48.60% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 5/14/2024 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 12/15/2023 |
| Downgrade | Jefferies: Buy to Hold | 12/15/2023 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 12/15/2023 |
| Initiated | William Blair: Outperform | 11/15/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/14/2023 |
Related Tickers
TVGN Tevogen Bio Holdings Inc.
0.8200
-7.87%
INKT MiNK Therapeutics, Inc.
1.0100
-2.88%
ACIU AC Immune SA
3.1800
-6.74%
ASMB Assembly Biosciences, Inc.
14.53
-1.29%
SPRO Spero Therapeutics, Inc.
1.5900
+1.27%
CTMX CytomX Therapeutics, Inc.
1.8900
-5.50%
FULC Fulcrum Therapeutics, Inc.
7.55
-3.14%
ALVR AlloVir, Inc.
0.7754
+3.19%
CDIO Cardio Diagnostics Holdings, Inc.
0.7300
-12.99%
CLRB Cellectar Biosciences, Inc.
3.3000
-0.90%